<DOC>
	<DOCNO>NCT03033134</DOCNO>
	<brief_summary>The purpose study confirm safety effectiveness BSJ003W Japanese patient non-valvular atrial fibrillation increase risk thromboembolism Japanese Clinical environment</brief_summary>
	<brief_title>A Study Evaluate Safety Effectiveness Left Atrial Appendage Closure Therapy Using BSJ003W</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>1 . The subject Japanese , 20 year old provide write informed consent participate trial 2 . The subject document paroxysmal , persistent permanent nonvalvular atrial fibrillation 3 . The subject calculate CHA2DS2VASc score 2 great recommend longterm oral anticoagulation therapy 4 . The subject deem physician suitable anticoagulant therapy appropriate rationale seek nonpharmacologic alternative warfarin 5 . The subject eligible come warfarin therapy LAA seal ( i.e . subject condition would require warfarin therapy ) . 1 . The subject prior stroke ( ischemic hemorrhagic ) transient ischemic attack within 90 day prior consent 2 . The subject myocardial infarction either nonST elevation ST elevation myocardial infarction within 90 day prior consent without intervention 3 . The subject planning cardiac ( e.g . cardioversion , coronary angiogram , percutaneous coronary intervention , cardiac ablation , etc . ) noncardiac invasive surgical procedure ( e.g . cataract surgery , endoscopy , etc . ) within 30 day prior 45 day BSJ003W implant 4 . The subject history atrial septal repair atrial septal defect/persistent foramen ovale device 5 . The subject implant mechanical valve prosthesis position 6 . The subject currently New York Heart Association class IV congestive heart failure 7 . The subject contraindicate aspirin 8 . The subject contraindicate seriously allergic thienopyridine 9 . The subject childbearing potential , plan become pregnant time study 10 . The subject able willing return require followup visit examination 11 . Subjects currently enrol another investigational study ( primary endpoint followup complete yet ) . 12 . The subject reason eligible study per investigator ' discretion .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>